Articles by Los Angeles Biotechnology Network News

No Picture
News

NextCure hires Celgene vet as CMO; José Vega leaves Merck to become Moderna’s chief safety officer

January 15, 2021 Los Angeles Biotechnology Network News Comments Off on NextCure hires Celgene vet as CMO; José Vega leaves Merck to become Moderna’s chief safety officer

NextCure has found its new CMO after the previous executive resigned last August.
Han Myint, a biopharma and academia veteran of more than 20 years, joined the company Thursday after serving as CMO at NexImmune for a little over a year. Myint had overs… […]

No Picture
HealthCoronavirusinfectious diseasepublic health

In LA, ambulances circle for hours and ICUs are full. Is this what Covid-19 has in store for the rest of the country?

January 15, 2021 Los Angeles Biotechnology Network News Comments Off on In LA, ambulances circle for hours and ICUs are full. Is this what Covid-19 has in store for the rest of the country?

Do the overwhelmed hospitals in Los Angeles offer a glimpse of what other regions may soon face as case counts rise steeply and a seemingly more infectious strain takes hold? […]

No Picture
News

City of Hope Scientists Have Developed a Precision Medicine Tool That Predicts If Chemotherapy Will Produce Debilitating Side Effects in Older Adults

January 14, 2021 Los Angeles Biotechnology Network News Comments Off on City of Hope Scientists Have Developed a Precision Medicine Tool That Predicts If Chemotherapy Will Produce Debilitating Side Effects in Older Adults

DUARTE, Calif.–(BUSINESS WIRE)–First-of-its-kind risk assessment tool developed by City of Hope helps oncologists make personalized treatment recommendations. […]

No Picture
News

Amgen tops cost watchdog’s price gougers list based on ‘unfounded’ increases for Enbrel without meaningful data

January 14, 2021 Los Angeles Biotechnology Network News Comments Off on Amgen tops cost watchdog’s price gougers list based on ‘unfounded’ increases for Enbrel without meaningful data

In a top 10 ranking of the most egregious price gougers from 2019, Amgen’s Enbrel topped US cost watchdog ICER’s naughty list with “unfounded” markups that added as much as $403 million to the nation’s drug spend during that time. Price increases for s… […]

No Picture
News

A much-hyped CV drug failed, repeatedly. Now, investors are betting nearly $200M on one last PhIII bid

January 14, 2021 Los Angeles Biotechnology Network News Comments Off on A much-hyped CV drug failed, repeatedly. Now, investors are betting nearly $200M on one last PhIII bid

Just under a decade ago, Eli Lilly announced early results for a new drug that lowered bad cholesterol and raised good cholesterol. It was a “holy grail” result, as JAMA put it in a press release, offering a path for a pill that could curb cardiovascul… […]

No Picture
News

Global WholeHealth Partners, Corp (OTC: GWHP) Announces New Purchase Agreement From RyZac Health as Order Size Increases Over 3 Times

January 13, 2021 Los Angeles Biotechnology Network News Comments Off on Global WholeHealth Partners, Corp (OTC: GWHP) Announces New Purchase Agreement From RyZac Health as Order Size Increases Over 3 Times

San Clemente, CA, Jan. 13, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Global WholeHealth Partners Corp, a multinational supplier of over 70+ with 56 products FDA approved and several approved for export only including Dengue, Ebola, Zika, Malaria a… […]

No Picture
Nasdaq:ARQTUS03969K1088

Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis

January 13, 2021 Los Angeles Biotechnology Network News Comments Off on Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis

WESTLAKE VILLAGE, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediated dermatological diseases and conditions, today a… […]

No Picture
Featured NewsUncategorized

An international team, including UCLA scientists, discover the dire wolf was a distinct species, different from the gray wolf

January 13, 2021 Los Angeles Biotechnology Network News Comments Off on An international team, including UCLA scientists, discover the dire wolf was a distinct species, different from the gray wolf

The post An international team, including UCLA scientists, discover the dire wolf was a distinct species, different from the gray wolf appeared first on Life Sciences.
[…]